A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against short seller Gotham ...

Below, we take a look at Grifols (GRFS), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Grifols (GRFS) secures a win in its defamation lawsuit against Gotham City Research in the U.S. Read more here.

One stock to keep an eye on is Grifols (GRFS). GRFS is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Another notable valuation metric for GRFS is its P/B ratio of 0.65.

Health Minister Khaled Abdel Ghaffar met on Sunday, June 1st, 2025, with Magdy Amin, Chairman of Grifols Egypt, to discuss expanding cooperation in haematology and the national plasma derivatives ...

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

Grifols (NASDAQ:GRFS) has marked a major win in its legal battle against Gotham City Research after a New York federal court declined a request made by the hedge fund seeking a dismissal of a ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.